A microfluidic device for accurate detection of hs-cTnI

Huang, Li; Su, Enben; Liu, Yuan; He, Nongyue; Deng, Yan; Jin, Lian; Chen, Zhu; Li, Song

doi:10.1016/j.cclet.2020.09.055

Cited by 39 publications

(16 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…( b ) The schematic illustration and digital image of the design of the proposed microfluidic-based chip. Figure adapted from Huang et al [ 64 ].…”

Section: Figurementioning

confidence: 99%

“…The proposed design could operate in the absence of the sample and conjugate pads while improving the precision of the chromatographic method by implementing Cy 5 fluorescent Microfluidic devices have shown great potential in biomedical applications, benefiting from the advantage of the precise control of biochemical reactions inside the microfluidic channel, thus favoring accurate detection. A microfluidic device for the specific and accurate detection of high-sensitivity cTnI was reported by Huang et al [64]. The proposed design could operate in the absence of the sample and conjugate pads while improving the precision of the chromatographic method by implementing Cy 5 fluorescent microspheres to which the cTnI antibodies were coupled.…”

Section: Fluorescence-based Immunosensorsmentioning

confidence: 99%

See 1 more Smart Citation

Cardiac Troponin Biosensor Designs: Current Developments and Remaining Challenges

Campu

Muresan

Craciun

et al. 2022

IJMS

View full text Add to dashboard Cite

Acute myocardial infarction (AMI) is considered as one of the main causes of death, threating human lives for decades. Currently, its diagnosis relies on electrocardiography (ECG), which has been proven to be insufficient. In this context, the efficient detection of cardiac biomarkers was proposed to overcome the limitations of ECG. In particular, the measurement of troponins, specifically cardiac troponin I (cTnI) and cardiac troponin T (cTnT), has proven to be superior in terms of sensitivity and specificity in the diagnosis of myocardial damage. As one of the most life-threatening conditions, specific and sensitive investigation methods that are fast, universally available, and cost-efficient to allow for early initiation of evidence-based, living-saving treatment are desired. In this review, we aim to present and discuss the major breakthroughs made in the development of cTnI and cTnT specific biosensor designs and analytical tools, highlighting the achieved progress as well as the remaining challenges to reach the technological goal of simple, specific, cheap, and portable testing chips for the rapid and efficient on-site detection of cardiac cTnI/cTnT biomarkers in order to diagnose and treat cardiovascular diseases at an incipient stage.

show abstract

“…( b ) The schematic illustration and digital image of the design of the proposed microfluidic-based chip. Figure adapted from Huang et al [ 64 ].…”

Section: Figurementioning

confidence: 99%

Section: Fluorescence-based Immunosensorsmentioning

confidence: 99%

Cardiac Troponin Biosensor Designs: Current Developments and Remaining Challenges

Campu

Muresan

Craciun

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Globally, liver cancer has the third highest fatality rate, second only to lung cancer and gastric cancer [ 3 ]. Liver cancer is difficult to detect at the early stage and develops rapidly, however, various devices developed recently may be modified and applied to detect it [ 111 , 112 , 113 ]. Conventional treatments of liver cancer include surgical resection, liver transplantation, radiotherapy, and chemotherapy, but these treatments suffer from side effects of varying degrees.…”

Section: Aptamer-bound Nanomaterials Used In Different Cancer Therapiesmentioning

confidence: 99%

Applications of Aptamer-Bound Nanomaterials in Cancer Therapy

et al. 2021

Self Cite

View full text Add to dashboard Cite

Cancer is still a major disease that threatens human life. Although traditional cancer treatment methods are widely used, they still have many disadvantages. Aptamers, owing to their small size, low toxicity, good specificity, and excellent biocompatibility, have been widely applied in biomedical areas. Therefore, the combination of nanomaterials with aptamers offers a new method for cancer treatment. First, we briefly introduce the situation of cancer treatment and aptamers. Then, we discuss the application of aptamers in breast cancer treatment, lung cancer treatment, and other cancer treatment methods. Finally, perspectives on challenges and future applications of aptamers in cancer therapy are discussed.

show abstract

“…7 In contrast, passive pumping techniques (e.g., surface tension, capillary force, hydrostatic, or hydrodynamic pressure) do not require any external power sources/pumps or actuators to drive fluid flow, thus facilitating a higher degree of miniaturization and consequently cost reduction. [33][34][35] Such methods have emerged as a simple and highly efficient means for fluid flow control in POC hematological and immunological test cartridges. In most commercialized cartridges for NA testing, nucleic acid preparation typically involves two separate steps: (1) NA release via lysis and (2) extraction (i.e., separation and purification) of the NA from complex samples containing inhibitors of qPCR via solid-phase extraction techniques, which rely on precise control of the liquid transfer into the specific cartridge chambers.…”

Section: Introductionmentioning

confidence: 99%